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Introduction:  Decreased platelet responsiveness to clopidogrel has been shown to be a risk factor of thrombotic complication after percutaneous 
coronary intervention (PCI) in Caucasians. However, this has not been verified in an Asian population. Previous studies have also shown that non-
Caucasian have higher mean post-treatment residual platelet reactivity than Caucasians. We studied whether decreased platelet responsiveness 
measured by VerifyNow, a point-of-care platelet function assay, is a risk factor of thrombotic complications after elective PCI in an Asian population.
Methods: We measured the platelet responsiveness with VerifyNow P2Y12 assay (Accumetrics Inc, San Diego, Calif) in 814 consecutive patients 
who underwent elective PCI with stent implantation. All patients received standard dual antiplatelet therapy for 12 months. Study endpoints were 
stent thrombosis and a composite of cardiovascular death or non-fatal MI at 12-month follow up.
Results: The mean P2Y12 reaction unit (PRU) and inhibition percent was 230.8 ±79.0 and 23.2 ± 21.0%, respectively. The optimal cut-off value 
for predicting 12- month stent thrombosis by receiver operating characteristic (ROC) curve analysis was percent inhibition <5% (AUC 0.772, 95% CI 
0.689-0.856, P=0.013) or platelet reaction unit(PRU) ≥275). The incidence of thrombotic complications was significantly higher in non-responder 
to clopidogrel, defined by PRU inhibition percent < 5% than in responders: stent thrombosis (2.1% vs 0%, P=0.01), cardiovascular death (1.5% vs 
0.6%, P=0.196) and non-fatal MI (1.8% vs 0.2%, P=0.022).
Conclusions: Mean platelet reactivity in this study was higher than those previously reported in Caucasians. Clopidogrel non-responsiveness, 
defined as P2Y12 inhibition percent < 5%, as well as PRU >275, was shown to be a risk factor of stent thrombosis, cardiovascular death and non-
fatal MI in elective PCI patients in this Korean population.
